The Pathophysiology of Graft-Versus-Host Disease

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 208-221

  Ferrara, James L M ^a   Antin, Joseph H ^b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Acute GVHD pathophysiology three step model; Effects of conditioning in hematopoietic cell transplantation; GVHD major barrier to wider application of allogeneic HCT; Modulation of donor T cells; Pathophysiology of graft versus host disease; Reduced T cell proliferation; Regulatory T cells; Toll like receptors and innate immunity

Indexed keywords

EID: 79961186038     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch16     Document Type: Chapter

References (213)

1. Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397-406.
2. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360-7.
3. Paris F, Fuks Z, Kang A et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293: 293-7.
4. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-13.
5. Teshima T, Ordemann R, Reddy P et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575-81.
6. Shlomchik WD, Couzens MS, Tang CB et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-15.
7. Beilhack A, Schulz S, Baker J et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005; 106: 1113-22.
8. Newton-Nash DK. The molecular basis of allorecognition. Assessment of the involvement of peptide. Hum Immunol 1994; 41: 105-11.
9. Sayegh MH, Perico N, Gallon L et al. Mechanisms of acquired thymic unresponsiveness to renal allografts. Thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy. Transplantation 1994; 58: 125-32.
10. Anderson BE, McNiff J, Yan J et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 2003; 112: 101-8.
11. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Host-reactive CD8+ memory stem cells in graftversus- host disease. Nat Med 2005; 11: 1299-305.
12. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996; 334: 281-5.
13. Martin PJ. How much benefit can be expected from matching for minor antigens in allogeneic marrow transplantation? Bone Marrow Transplant 1997; 20: 97-100.
14. Nash RA, Pepe MS, Storb R et al. Acute graftversus- host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-45.
15. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997; 157: 125-40.
16. Dickinson AM, Wang XN, Sviland L et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002; 8: 410-14.
17. Dustin ML, Springer TA. T-cell receptor crosslinking transiently stimulates adhesiveness through LFA-1. Nature 1989; 341: 619-24.
18. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25: 139-70.
19. Merad M, Hoffmann P, Ranheim E et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004; 10: 510-17.
20. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5.
21. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-95.
22. Holler E, Rogler G, Brenmoehl J et al. Prognostic significance of NOD2/CARD15 variants in HLAidentical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006; 107: 4189-93.
23. Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 2001; 193: F5-9.
24. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK. Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001; 410: 101-5.
25. Ordemann R, Hutchinson R, Friedman J et al. Enhanced allostimulatory activity of host antigenpresenting cells in old mice intensifies acute graftversus- host disease. J Clin Invest 2002; 109: 1249-56.
26. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-100.
27. Ruggeri L, Capanni M, Martelli MF, Velardi A. Cellular therapy: exploiting NK cell alloreactivity in transplantation. Curr Opin Hematol 2001; 8: 355-9.
28. Samelson LE, Patel MD, Weissman AM, Harford JB, Klausner RD. Antigen activation of murine T cells induces tyrosine phosphorylation of a polypeptide associated with the T cell antigen receptor. Cell 1986; 46: 1083-90.
29. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-57.
30. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-52.
31. Rissoan MC, Soumelis V, Kadowaki N et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183-6.
32. Carvalho-Pinto CE, Garcia MI, Mellado M et al. Autocrine production of IFN-gamma by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/ lpr mice. J Immunol 2002; 169: 1058-67.
33. Via CS, Finkelman FD. Critical role of interleukin- 2 in the development of acute graft-versushost disease. Int Immunol 1993; 5: 565-72.
34. Malkovsky M, Brenner MK, Hunt R et al. T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2. Cell Immunol 1986; 103: 476-80.
35. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 1992; 327: 1613-17.
36. Schwarer AP, Jiang YZ, Brookes PA et al. Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 1993; 341: 203-5.
37. Ferrara JL, Marion A, McIntyre JF, Murphy GF, Burakoff SJ. Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody. J Immunol 1986; 137: 1874-7.
38. Herve P, Wijdenes J, Bergerat JP et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin- 2 receptor monoclonal antibody (B-B10). Blood 1990; 75: 1017-23.
39. Anasetti C, Martin PJ, Hansen JA et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graftversus- host disease. Transplantation 1990; 50: 49-54.
40. Li XC, Demirci G, Ferrari-Lacraz S et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med 2001; 7: 114-18.
41. Kumaki S, Minegishi M, Fujie H et al. Prolonged secretion of IL-15 in patients with severe forms of acute graft-versus-host disease after allogeneic bone marrow transplantation in children. Int J Hematol 1998; 67: 307-12.
42. Szebeni J, Wang MG, Pearson DA, Szot GL, Sykes M. IL-2 inhibits early increases in serum gamma interferon levels associated with graftversus- host-disease. Transplantation 1994; 58: 1385-93.
43. Troutt AB, Maraskovsky E, Rogers LA, Pech MH, Kelso A. Quantitative analysis of lymphokine expression in vivo and in vitro. Immunol Cell Biol 1992; 70(Pt 1): 51-7.
44. Velardi A, Varese P, Terenzi A et al. Lymphokine production by T-cell clones after human bone marrow transplantation. Blood 1989; 74: 1665-72.
45. Dickinson AM, Sviland L, Dunn J, Carey P, Proctor SJ. Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro human skin explant model. Bone Marrow Transplant 1991; 7: 209-16.
46. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168: 3195-204.
47. Mowat AM. Antibodies to IFN-gamma prevent immunologically mediated intestinal damage in murine graft-versus-host reaction. Immunology 1989; 68: 18-23.
48. Holda JH, Maier T, Claman HN. Evidence that IFN-gamma is responsible for natural suppressor activity in GVHD spleen and normal bone marrow. Transplantation 1988; 45: 772-7.
49. Wall DA, Hamberg SD, Reynolds DS, Burakoff SJ, Abbas AK, Ferrara JL. Immunodeficiency in graft-versus-host disease. I. Mechanism of immune suppression. J Immunol 1988; 140: 2970-6.
50. Krenger W, Falzarano G, Delmonte J Jr, Snyder KM, Byon JC, Ferrara JL. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood 1996; 88: 1113-21.
51. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405-13.
52. Yang YG, Dey BR, Sergio JJ, Pearson DA, Sykes M. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest 1998; 102: 2126-35.
53. Reddy P, Teshima T, Kukuruga M et al. Interleukin- 18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001; 194: 1433-40.
54. Fowler DH, Kurasawa K, Husebekk A, Cohen PA, Gress RE. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. J Immunol 1994; 152: 1004-13.
55. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540-9.
56. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422-9.
57. Krenger W, Snyder K, Smith S, Ferrara JL. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 1994; 58: 1251-7.
58. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995; 85: 842-51.
59. Sykes M, Hoyles KA, Romick ML, Sachs DH. In vitro and in vivo analysis of bone marrow-derived CD3+, CD4-, CD8-, NK1.1+ cell lines. Cell Immunol 1990; 129: 478-93.
60. Brok HP, Heidt PJ, van der Meide PH, Zurcher C, Vossen JM. Interferon-gamma prevents graftversus- host disease after allogeneic bone marrow transplantation in mice. J Immunol 1993; 151: 6451-9.
61. Wall DA, Sheehan KC. The role of tumor necrosis factor and interferon gamma in graft-versushost disease and related immunodeficiency. Transplantation 1994; 57: 273-9.
62. Li XC, Strom TB, Turka LA, Wells AD. T cell death and transplantation tolerance. Immunity 2001; 14: 407-16.
63. Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27: 20-1.
64. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-6.
65. Liu W, Putnam AL, Xu-Yu Z et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701-11.
66. Seddiki N, Santner-Nanan B, Martinson J et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693-700.
67. Janssens W, Carlier V, Wu B, VanderElst L, Jacquemin MG, Saint-Remy JM. CD4+CD25+ T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner. J Immunol 2003; 171: 4604-12.
68. Cederbom L, Hall H, Ivars F. CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000; 30: 1538-43.
69. Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 2003; 63: 4516-20.
70. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 1996; 183: 2669-74.
71. Hoffmann P, Edinger M. CD4+CD25+ regulatory T cells and graft-versus-host disease. Semin Hematol 2006; 43: 62-9.
72. Edinger M, Hoffmann P, Ermann J et al. CD4+CD25+ regulatory T cells preserve graftversus- tumor activity while inhibiting graftversus- host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-50.
73. Zeiser R, Nguyen VH, Beilhack A et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin- dependent interleukin-2 production. Blood 2006; 108: 390-9.
74. Nguyen VH, Zeiser R, Dasilva DL et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graftversus- host disease following allogeneic transplantation. Blood 2007; 109: 2649-56.
75. Nguyen VH, Zeiser R, Negrin RS. Role of naturally arising regulatory T cells in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 995-1009.
76. Lan F, Zeng D, Higuchi M, Huie P, Higgins JP, Strober S. Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: "natural suppressor" cells. J Immunol 2001; 167: 2087-96.
77. Kagi D, Vignaux F, Ledermann B et al. Fas and perforin pathways as major mechanisms of T cellmediated cytotoxicity. Science 1994; 265: 528-30.
78. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650-2.
79. Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 1998; 10: 581-7.
80. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-95.
81. Chinnaiyan AM, O'Rourke K, Yu GL et al. Signal transduction by DR3, a death domaincontaining receptor related to TNFR-1 and CD95. Science 1996; 274: 990-2.
82. Chicheportiche Y, Fossati-Jimack L, Moll S, Ibnou-Zekri N, Izui S. Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun 2000; 279: 162-5.
83. Ueno Y, Ishii M, Yahagi K et al. Fas-mediated cholangiopathy in the murine model of graft versus host disease. Hepatology 2000; 31: 966-74.
84. Shustov A, Nguyen P, Finkelman F, Elkon KB, Via CS. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation of IFN-gamma production. J Immunol 1998; 161: 2848-55.
85. Wasem C, Frutschi C, Arnold D et al. Accumulation and activation-induced release of preformed Fas (CD95) ligand during the pathogenesis of experimental graft-versus-host disease. J Immunol 2001; 167: 2936-41.
86. Liem LM, van Lopik T, van Nieuwenhuijze AE, van Houwelingen HC, Aarden L, Goulmy E. Soluble Fas levels in sera of bone marrow transplantation recipients are increased during acute graft-versus-host disease but not during infections. Blood 1998; 91: 1464-8.
87. Kayaba H, Hirokawa M, Watanabe A et al. Serum markers of graft-versus-host disease after bone marrow transplantation. J Allergy Clin Immunol 2000; 106: S40-4.
88. Baker MB, Riley RL, Podack ER, Levy RB. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc Natl Acad Sci U S A 1997; 94: 1366-71.
89. Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 1996; 157: 5387-93.
90. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997; 3: 409-13.
91. van Den Brink MR, Moore E, Horndasch KJ et al. Fas-deficient lpr mice are more susceptible to graft-versus-host disease. J Immunol 2000; 164: 469-80.
92. Hattori K, Hirano T, Miyajima H et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graftversus- host disease pathologies. Blood 1998; 91: 4051-5.
93. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 1996; 183: 2645-56.
94. Hattori Y, Sakuma I, Kanno M. Differential effects of histamine mediated by histamine H1- and H2-receptors on contractility, spontaneous rate and cyclic nucleotides in the rabbit heart. Eur J Pharmacol 1988; 153: 221-9.
95. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987; 166: 1280-9.
96. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1988; 141: 2629-34.
97. Hill GR, Teshima T, Rebel I et al. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. J Immunol 2000; 164: 656-63.
98. Brown GR, Lee E, Thiele DL. TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J->C57BL/6J × bm12)F1 mice. J Immunol 2002; 168: 3065-71.
99. Murphy GF, Sueki H, Teuscher C, Whitaker D, Korngold R. Role of mast cells in early epithelial target cell injury in experimental acute graftversus- host disease. J Invest Dermatol 1994; 102: 451-61.
100. Cooke KR, Hill GR, Gerbitz A et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 2000; 70: 272-9.
101. Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-16.
102. Holler E, Kolb HJ, Hintermeier-Knabe R et al. Role of tumor necrosis factor alpha in acute graftversus- host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 1993; 25: 1234-6.
103. Tanaka J, Imamura M, Kasai M et al. Cytokine receptor gene expression in peripheral blood mononuclear cells during graft-versus-host disease after allogeneic bone marrow transplantation. Leuk Lymphoma 1995; 19: 281-7.
104. Abhyankar S, Gilliland DG, Ferrara JL. Interleukin- 1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation 1993; 56: 1518-23.
105. Antin JH, Weisdorf D, Neuberg D et al. Interleukin- 1 blockade does not prevent acute graftversus- host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin- 1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002; 100: 3479-82.
106. Falzarano G, Krenger W, Snyder KM, Delmonte J Jr, Karandikar M, Ferrara JL. Suppression of B-cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-alpha in mice with acute graft-versus-host disease. Blood 1996; 87: 2853-60.
107. Nestel FP, Greene RN, Kichian K, Ponka P, Lapp WS. Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis. Blood 2000; 96: 1836-43.
108. Weiss G, Schwaighofer H, Herold M et al. Nitric oxide formation as predictive parameter for acute graft-versus-host disease after human allogeneic bone marrow transplantation. Transplantation 1995; 60: 1239-44.
109. Cooke KR, Hill GR, Crawford JM et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 1998; 102: 1882-91.
110. Price KS, Nestel FP, Lapp WS. Progressive accumulation of bacterial lipopolysaccharide in vivo during murine acute graft-versus-host disease. Scand J Immunol 1997; 45: 294-300.
111. Raetz CR. Biochemistry of endotoxins. Annu Rev Biochem 1990; 59: 129-70.
112. Fegan C, Poynton CH, Whittaker JA. The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplant 1990; 5: 373-7.
113. Cooke KR, Gerbitz A, Crawford JM et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107: 1581-9.
114. van Bekkum DW, Roodenburg J, Heidt PJ, van der Waaij D. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974; 52: 401-4.
115. Jackson SK, Parton J, Barnes RA, Poynton CH, Fegan C. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. Eur J Clin Invest 1993; 23: 540-5.
116. Storb R, Prentice RL, Buckner CD et al. Graftversus- host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983; 308: 302-7.
117. Beelen DW, Haralambie E, Brandt H et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 1992; 80: 2668-76.
118. Beelen DW, Elmaagacli A, Muller KD, Hirche H, Schaefer UW. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93: 3267-75.
119. Gerbitz A, Schultz M, Wilke A et al. Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. Blood 2004; 103: 4365-7.
120. Cohen JL, Boyer O, Salomon B et al. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 1997; 89: 4636-45.
121. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001; 2: 123-8.
122. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-12.
123. Murai M, Yoneyama H, Harada A et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versushost disease. J Clin Invest 1999; 104: 49-57.
124. Serody JS, Burkett SE, Panoskaltsis-Mortari A et al. T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 2000; 96: 2973-80.
125. Panoskaltsis-Mortari A, Strieter RM, Hermanson JR et al. Induction of monocyte- and Tcell- attracting chemokines in the lung during the generation of idiopathic pneumonia syndrome following allogeneic murine bone marrow transplantation. Blood 2000; 96: 834-9.
126. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004; 4: 211-22.
127. Berlin C, Berg EL, Briskin MJ et al. [alpha]4 [beta]7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993; 74: 185.
128. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2: 947-50.
129. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-8.
130. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298-300.
131. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-63.
132. Badros A, Barlogie B, Siegel E et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloabla tive conditioning. J Clin Oncol 2002; 20: 1295-303.
133. Ho VT, Soiffer RJ. The history and future of Tcell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192-204.
134. Wagner JE, Santos GW, Noga SJ et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood 1990; 75: 1370-7.
135. Kernan NA, Collins NH, Juliano L, Cartagena T, Dupont B, O'Reilly RJ. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986; 68: 770-3.
136. Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-93.
137. Martin PJ, Hansen JA, Buckner CD et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66: 664-72.
138. Martin PJ, Rowley SD, Anasetti C et al. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood 1999; 94: 2192-9.
139. Antin JH, Bierer BE, Smith BR et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139-49.
140. Soiffer RJ, Weller E, Alyea EP et al. CD6+ donor marrow T-cell depletion as the sole form of graftversus- host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol 2001; 19: 1152-9.
141. Papadopoulos EB, Carabasi MH, Castro- Malaspina H et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083-90.
142. Champlin R, Ho W, Gajewski J et al. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990; 76: 418-23.
143. Montero A, Savani BN, Kurlander R et al. Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. Br J Haematol 2005; 130: 733-9.
144. Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502-5.
145. Greenberg PD, Riddell SR. Deficient cellular immunity -finding and fixing the defects. Science 1999; 285: 546-51.
146. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005; 366: 733-41.
147. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S et al. Immune reconstitution without graftversus- host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002; 360: 130-7.
148. Koh MB, Prentice HG, Corbo M, Morgan M, Cotter FE, Lowdell MW. Alloantigen-specific Tcell depletion in a major histocompatibility complex fully mismatched murine model provides effective graft-versus-host disease prophylaxis in the presence of lymphoid engraftment. Br J Haematol 2002; 118: 108-16.
149. Bacigalupo A, Lamparelli T, Barisione G et al. Thymoglobulin prevents chronic graft-versushost disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560-5.
150. Morris E, Thomson K, Craddock C et al. Outcomes after alemtuzumab-containing reducedintensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865-71.
151. Storb R, Deeg HJ, Thomas ED et al. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 1985; 66: 698-702.
152. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729-34.
153. Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-8.
154. Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-14.
155. Chao NJ, Snyder DS, Jain M et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective doubleblind randomized trial. Biol Blood Marrow Transplant 2000; 6: 254-61.
156. Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99: 2586-91.
157. Auffermann-Gretzinger S, Eger L, Schetelig J, Bornhauser M, Heidenreich F, Ehninger G. Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia. Transplantation 2007; 83: 1268-72.
158. Storb R, Epstein RB, Graham TC, Thomas ED. Methotrexate regimens for control of graft-versushost disease in dogs with allogeneic marrow grafts. Transplantation 1970; 9: 240-6.
159. Santos GW, Sensenbrenner LL, Burke PJ et al. Marrow transplantation in man following cyclophosphamide. Transplant Proc 1971; 3: 400-4.
160. Lazarus HM, Coccia PF, Herzig RH et al. Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in allogeneic bone marrow transplant patients. Blood 1984; 64: 215-20.
161. Ramsay NK, Kersey JH, Robison LL et al. A randomized study of the prevention of acute graftversus- host disease. N Engl J Med 1982; 306: 392-7.
162. Durakovic N, Radojcic V, Powell J, Luznik L. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versusleukemia reactivity. Transplantation 2007; 83: 631-40.
163. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
164. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-40.
165. Li Y, Zheng XX, Li XC, Zand MS, Strom TB. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66: 1387-8.
166. Lai JH, Tan TH. CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin. J Biol Chem 1994; 269: 30077-80.
167. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298-302.
168. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995; 55: 1982-8.
169. Miyazaki T, Liu ZJ, Kawahara A et al. Three distinct IL-2 signaling pathways mediated by bcl- 2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell 1995; 81: 223-31.
170. Malik RK, Parsons JT. Integrin-dependent activation of the p70 ribosomal S6 kinase signaling pathway. J Biol Chem 1996; 271: 29785-91.
171. Murray AG, Schechner JS, Epperson DE et al. Dermal microvascular injury in the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and rapamycin. Am J Pathol 1998; 153: 627-38.
172. Cutler C, Li S, Ho VT et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109: 3108-14.
173. Passweg JR, Tiberghien P, Cahn JY et al. Graftversus- leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 21: 153-8.
174. Bostrom L, Ringden O, Gratama JW et al. A role of herpes virus serology for the development of acute graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1990; 5: 321-6.
175. Huang XJ, Wan J, Lu DP. Serum TNFalpha levels in patients with acute graft-versus-host disease after bone marrow transplantation. Leukemia 2001; 15: 1089-91.
176. Herve P, Flesch M, Tiberghien P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362-8.
177. Holler E, Kolb HJ, Mittermuller J et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 86: 890-9.
178. Levine JE, Paczesny S, Mineishi S et al. Etanercept plus methylprednisolone as initial therapy for acute GVHD. Blood 2008; 111: 2470-5.
179. Sackstein R. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant 2006; 12: 2-8.
180. Waldmann H, Chen TC, Graca L et al. Regulatory T cells in transplantation. Semin Immunol 2006; 18: 111-19.
181. Dutt S, Ermann J, Tseng D et al. L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. Blood 2005; 106: 4009-15.
182. Hashimoto D, Asakura S, Matsuoka K et al. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graftversus- host disease. Eur J Immunol 2007; 37: 271-81.
183. Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003; 111: 659-69.
184. Shapira M, Adler SN, Jacob H, Resnick IB, Slavin S, Or R. New insights into the pathophysiology of gastrointestinal graft-versus-host disease using capsule endoscopy. Haematologica 2005; 90: 1003-4.
185. Shapira MY, Hirshfeld E, Weiss L et al. Mycophenolate mofetil does not suppress the graftversus- leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model. Cancer Immunol Immunother 2005; 54: 383-8.
186. Shapira MY, Resnick IB, Bitan M et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versushost disease: a preliminary report. Bone Marrow Transplant 2005; 36: 1097-101.
187. Shulman HM, Sale GE, Lerner KG et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978; 91: 545-70.
188. Filipovich AH, Weisdorf D, Pavletic S et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-6.
189. Parkman R. Clonal analysis of murine graft-vshost disease. I. Phenotypic and functional analysis of T lymphocyte clones. J Immunol 1986; 136: 3543-8.
190. Patriarca F, Skert C, Sperotto A et al. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graftvs- host disease and immune recovery. Exp Hematol 2006; 34: 389-96.
191. Zhang C, Todorov I, Zhang Z et al. Donor CD4+ T and B cells in transplants induce chronic graftversus- host disease with autoimmune manifestations. Blood 2006; 107: 2993-3001.
192. Zhang Y. Clinical study on pulmonary complications after allogeneic peripheral blood stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi 2006; 27: 366-9.
193. Ellison CA, Bradley DS, Fischer JM, Hayglass KT, Gartner JG. Murine graft-versus-host disease induced using interferon-gamma-deficient grafts features antibodies to double-stranded DNA, T helper 2-type cytokines and hypereosinophilia. Immunology 2002; 105: 63-72.
194. Zhang W, Zeng Y-S, Zhang X-B, Wang J-M, Zhang W, Chen S-J. Combination of adenoviral vector-mediated neurotrophin-3 gene transfer and retinoic acid promotes adult bone marrow cells to differentiate into neuronal phenotypes. Neurosci Letts 2006; 408: 98.
195. Zorn E, Kim HT, Lee SJ et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005; 106: 2903-11.
196. Rezvani K, Mielke S, Ahmadzadeh M et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291-7.
197. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006; 25: 195-201.
198. Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG. B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2001; 2: 1126-32.
199. Sakaguchi S, Sakaguchi N. Thymus and autoimmunity. Transplantation of the thymus from cyclosporine A-treated mice causes organ-specific autoimmune disease in athymic nude mice. J Exp Med 1988; 167: 1479-85.
200. Jones EY, Stuart DI, Walker NP. Structure of tumour necrosis factor. Nature 1989; 338: 225-8.
201. Yeager AM, Wagner JE Jr, Graham ML, Jones RJ, Santos GW, Grochow LB. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425-8.
202. Brochu S, Rioux-Masse B, Roy J, Roy DC, Perreault C. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease. Blood 1999; 94: 390-400.
203. Cutler C, Antin JH. Chronic graft-versus-host disease. Curr Opin Oncol 2006; 18: 126-31.
204. Ratanatharathorn V, Ayash L, Reynolds C et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003; 9: 505-11.
205. Zaja F, Bacigalupo A, Patriarca F et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007; 40: 273-7.
206. Groh V, Li YQ, Cioca D et al. Efficient crosspriming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A 2005; 102: 6461-6.
207. Hon H, Oran A, Brocker T, Jacob J. B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. J Immunol 2005; 174: 5233-42.
208. Miklos DB, Kim HT, Miller KH et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973-8.
209. Zorn E, Miklos DB, Floyd BH et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med 2004; 199: 1133-42.
210. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002; 99: 3319-25.
211. Svegliati S, Olivieri A, Campelli N et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007; 110: 237-41.
212. Harbers SO, Crocker A, Catalano G et al. Antibody- enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 2007; 117: 1361-9.
213. Tivol E, Komorowski R, Drobyski WR. Emergent autoimmunity in graft-versus-host disease. Blood 2005; 105: 4885-91.